BBI608

DRUG16 trials

Sponsors

Sumitomo Pharma America, Inc., NCIC Clinical Trials Group, Sumitomo Pharma Co., Ltd., Australasian Gastro-Intestinal Trials Group

Conditions

Advanced Gastrointestinal CancerAdvanced Solid TumorsCancerCancer, Advanced MalignanciesColorectal CancerColorectal Cancer MetastaticColorectal CarcinomaGastric Cancer

Phase 1

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

CompletedNCT01325441

Sumitomo Pharma America, Inc.Cancer

Start: 2011-04-30End: 2021-06-01Updated: 2023-11-15

A Study of BBI608 in Adult Patients With Advanced Malignancies

CompletedNCT01775423

Sumitomo Pharma America, Inc.Cancer, Advanced Malignancies

Start: 2009-03-31End: 2015-08-06Updated: 2023-11-14

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

CompletedNCT02024607

Sumitomo Pharma America, Inc.Advanced Gastrointestinal Cancer

Start: 2014-01-31End: 2019-11-30Updated: 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

CompletedNCT02231723

Sumitomo Pharma America, Inc.Metastatic Pancreatic Adenocarcinoma

Start: 2014-08-31End: 2020-06-30Updated: 2023-11-18

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

CompletedNCT02279719

Sumitomo Pharma America, Inc.Hepatocellular Carcinoma

Start: 2014-12-31End: 2019-10-31Updated: 2023-11-15

A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

CompletedNCT02315534

Sumitomo Pharma America, Inc.Glioblastoma

Start: 2015-03-31End: 2019-06-24Updated: 2023-11-15

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

CompletedNCT02347917

Sumitomo Pharma Co., Ltd.Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer

Start: 2015-02-28End: 2018-05-31Updated: 2022-04-12

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

CompletedNCT02352558

Sumitomo Pharma America, Inc.Hematologic Malignancy

Start: 2015-05-31End: 2019-05-16Updated: 2023-11-14

A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma

CompletedNCT02358395

Sumitomo Pharma Co., Ltd.Hepatocellular Carcinoma

Start: 2015-02-28End: 2017-11-30Target: 12Updated: 2022-04-12

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

CompletedNCT02432326

Sumitomo Pharma America, Inc.Advanced Solid Tumors, Cancer

Start: 2015-04-30End: 2020-04-30Updated: 2023-11-08

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

CompletedNCT02467361

Sumitomo Pharma America, Inc.Cancer

Start: 2015-08-31End: 2021-01-29Updated: 2023-11-14

A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer

CompletedNCT02641873

Sumitomo Pharma Co., Ltd.Metastatic Colorectal Cancer

Start: 2015-12-31End: 2017-01-31Updated: 2022-04-12

Phase 2

A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

CompletedNCT01776307

Sumitomo Pharma America, Inc.Colorectal Cancer

Start: 2012-03-31End: 2020-04-30Updated: 2023-11-15

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

CompletedNCT03647839

Australasian Gastro-Intestinal Trials GroupColorectal Cancer Metastatic

Start: 2018-09-06End: 2021-04-09Updated: 2021-08-27

Phase 3

BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma

CompletedNCT01830621

NCIC Clinical Trials GroupColorectal Carcinoma

Start: 2013-05-10End: 2016-05-16Updated: 2023-08-28

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

CompletedNCT02178956

Sumitomo Pharma America, Inc.Gastric Cancer, Gastroesophageal Junction Cancer

Start: 2014-10-31End: 2017-09-20Updated: 2023-11-15

Related Papers

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma.

2023-05-158 citations

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical Cancer Research2022-05-2617 citations

Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers

Clinical Pharmacology in Drug Development2021-06-095 citations

Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs).

Journal of Clinical Oncology2021-05-20

Effect of food on exposure to napabucasin: Data from two phase I studies.

Journal of Clinical Oncology2021-01-20

CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress

Annals of Oncology2018-06-013 citations

CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress

Annals of Oncology2018-06-012 citations

The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Journal of Clinical Oncology2018-05-2020 citations

Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).

Journal of Clinical Oncology2018-05-2016 citations

A phase 1b study of napabucasin (NAPA) + weekly paclitaxel (PTX) in patients (pts) with advanced thymoma and thymic carcinoma.

Journal of Clinical Oncology2018-05-205 citations

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

2018-02-01135 citations

A Clinical Trial Protocol Paper Discussing the Brighter Study

Future Oncology2018-01-0318 citations

A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).

Journal of Clinical Oncology2017-05-2016 citations

Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

Journal of Clinical Oncology2017-05-2014 citations

BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM).

Journal of Clinical Oncology2017-05-208 citations

A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.

Journal of Clinical Oncology2017-05-204 citations

A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated non-squamous non-small cell lung cancer.

Journal of Clinical Oncology2017-05-204 citations

A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer.

Journal of Clinical Oncology2017-05-204 citations

A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.

Journal of Clinical Oncology2017-05-203 citations

A phase 1b study of napabucasin plus weekly paclitaxel in patients with advanced thymoma and thymic carcinoma.

Journal of Clinical Oncology2017-05-201 citations

20 more papers not shown